Collegium Pharmaceutical, Inc. announced it will present two posters highlighting real-world data from its neuropsychiatry product, Jornay PM, at the National Association of Pediatric Nurse Practitioners (NAPNAP) 46th National Conference on Pediatric Health Care. The conference is being held in Chicago, IL, from March 10-13, 2025. This presentation aims to demonstrate the real-world benefit of Jornay PM.
Thomas Smith, M.D., Chief Medical Officer, stated that the data being presented demonstrates Jornay PM's value as an important therapeutic option for the ADHD community. Jornay PM is a central nervous system stimulant indicated for the treatment of attention deficit hyperactivity disorder in patients six years and older. Many home-based difficulties for children and adolescents with ADHD occur during the early morning routine.
The poster presentations will be available to attendees in the Riverside Center Exhibit Hall during exhibit hours on Monday, March 10, and Tuesday, March 11. This initiative supports Collegium's commitment to providing differentiated medicines that improve the lives of people living with serious medical conditions.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.